The deal activity in the pharma world continues apace, as the question remains: who is going to bid for whom next? Shire has put in a hostile US$30bn bid for fellow rare disease medicine supplier, Baxalta. Just nine months previously, Shire was itself nearly sold to Abbvie, before the deal collapsed. Baxalta specialises in haemophilia,… Learn more
Trending Articles
More Pages to Explore .....